Diabetes Self-Management Blog

Get tips and insights from health-care professionals and people with diabetes, share your thoughts, and ask questions on our blog.

Sign up for our weekly e-mail newsletter and receive a FREE GIFT! Enter your e-mail below.



 

Learn more
Sample e-newsletter

Learn more about diabetes

Links to help you learn more about diabetes.

Ask a diabetes expert
Other diabetes resources
Browse article topics

 

A new study of the lipid-lowering drug fenofibrate (brand names TriCor, Lofibra, and others) has shown that taking it alone may not cut the risk of heart disease in people with Type 2 diabetes.

In a substudy from the Fenofibrate Intervention and Event Lowering in Diabetes (or FIELD) study, 170 people with Type 2 diabetes were randomly assigned to take fenofibrate or a placebo for five years. During this period, the researchers found that atherosclerosis — narrowing of arteries caused by the buildup of fatty plaque that is associated with heart disease, stroke, and peripheral vascular disease — progressed at the same rate in both study groups.

These findings are consistent with the main results of the FIELD study, which found that taking fenofibrate did not lower the rate of “coronary events” (heart attack and death from heart disease) in 9,795 people with Type 2 diabetes. These results were published in 2005 in the journal The Lancet. (See the study abstract here.)

However, fenofibrate may still be effective when used in combination with other cholesterol- and triglyceride-lowering drugs, such as statins. Commenting in 2005 on the main FIELD study results, lead researcher Professor Anthony Keech said, “In the context of the well established benefits of statin therapy in this patient group, the main use of fenofibrate will probably be in combination therapy. This question needs to be considered in future studies.”

I reported on one such study earlier this year (see “Two Lipid Drugs May Be Better Than One”). That shorter-term study found that people who took the statin drug simvastatin and fenofibrate together had fewer markers for cardiovascular disease risk after 12 weeks than those who took either drug alone. That study was paid for by the manufacturers of brand-name simvastatin (Zocor) and fenofibrate (TriCor), although generic versions of these drugs are available, too.

You can find the abstract for the new FIELD substudy in the Journal of the American College of Cardiology online here.

POST A COMMENT       


Comments
  1. Then what are people like me to do? I have serious side effects to statins, mainly the muscle weakness and pain and I have been advised by a specialist to never take statins again. I have been on Trico for years and had a heart attack this past July. I have since had Welchol added to my drug list. My next blood work will be in January so I don’t know what my numbers will be till then. Is this the only route I can go?

    Posted by pghshopper |
  2. I am another who cannot take statins and most other prescription drugs. I’ve spent the last 7 years in and out of a wheelchair because of the muscle weakness. These drugs have destroyed the quality of my life, yet they are touted as safe by doctors and the drug companies. When will this “you must take this drug” drug madness stop?

    Posted by tweety |
  3. Dear Tara. Happy hollidays. And thanks for everything a great web site.

    Posted by CalgaryDiabetic |
  4. Very nice.Drug Intervention

    Posted by symonds |

Post a Comment

Note: All comments are moderated and there may be a delay in the publication of your comment. Please be on-topic and appropriate. Do not disclose personal information. For more information, please read our Terms and Conditions.


Type 2 Diabetes
It's Not Over 'til Somebody Sings (11/03/09)
Syringe Recall; New Treatment Recommendations Released (10/30/09)
Pollution and Diabetes (10/26/09)
Insulin Effective and Accepted in Newly Diagnosed Type 2s (10/16/09)

Oral Medicines
Diabetes Drugs: Meglitinides (10/09/09)
Affordable Drug Combo Slashes Heart Risk by As Much As 80% (10/09/09)
Diabetes Drugs: DPP-4 Inhibitors (10/15/09)
Diabetes Drugs: Sulfonylureas (09/22/09)

Heart Health
Affordable Drug Combo Slashes Heart Risk by As Much As 80% (10/09/09)
My Cholesterol, My LDL, and That Statin Dose (10/08/09)
Is Weight Good for You? (07/01/09)
Tight Control OK if You Want It (06/30/09)

Diabetes Research
The Joys of Marketing (11/04/09)
Study Links Depression and Early Stages of Chronic Kidney Disease (10/23/09)
Pollution and Diabetes (10/26/09)
Affordable Drug Combo Slashes Heart Risk by As Much As 80% (10/09/09)

Diabetes News
"Swine" Flu Vaccine to be Available Shortly (10/22/09)
Lantus and Cancer: Further Study Needed (07/01/09)
Research on Rosiglitazone (06/12/09)
News Roundup (06/11/09)

 

 

Disclaimer of Medical Advice: You understand that the blog posts and comments to such blog posts (whether posted by us, our agents or bloggers, or by users) do not constitute medical advice or recommendation of any kind, and you should not rely on any information contained in such posts or comments to replace consultations with your qualified health care professionals to meet your individual needs. The opinions and other information contained in the blog posts and comments do not reflect the opinions or positions of the Site Proprietor.


Common Foot Problems and Their Solutions
Don’t let these common foot problems slow you down. Here’s how to do away with foot pain, dry skin, calluses, and more.

Medicare Information
A list of books, Web sites, and phone numbers to help you learn more about Medicare

How Much Do You Know About Depression?
Depression is even more common among people with diabetes than among the general public. This quiz reveals facts about its causes, symptoms, and treatments.

Complete table of contents
Get a FREE ISSUE
Subscription questions